| Bioactivity | Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors[1]. |
| In Vivo | Rosmantuzumab (25 mg/kg；腹腔注射，每周一次，持续 4 周) 显著保护动物免于发生肝纤维化[1]。Rosmantuzumab (25mg /kg；腹腔注射，每两周一次，持续 6 周) 在博莱霉素诱导的肺纤维化小鼠模型中，显著抑制皮肤厚度、胶原沉积和 α-SMA 阳性细胞数量[1]。 Animal Model: |
| Name | Rosmantuzumab |
| CAS | 1684393-04-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang M, et al. Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. PLoS One. 2020 Mar 11;15(3):e0229445. |